Monitor for prospectus supplement filing to determine offering size, pricing, and dilution level. Given the small market cap and lack of U.S. revenue, even a modest offering could result in significant dilution. Consider short-term downside pressure on stock price as offering approaches.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 24 $0.1980entry
- T+1 · 8mo ago +5.05%α +4.49% · $0.2080
- T+5 · 8mo ago +4.04%α +4.48% · $0.2060
- T+20 · 7mo ago +46.46%α +37.58% · $0.2900
- T+60 · 5mo ago +697.98%α +683.36% · $1.58
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Outlook Therapeutics announced a best-efforts public offering of common stock or pre-funded warrants, along with accompanying warrants, to raise capital for working capital and general corporate purposes. The offering is being managed by H.C. Wainwright & Co. and is subject to market conditions with no guaranteed size or completion. This is a dilutive capital raise by a small-cap biopharma company without commercial revenue in the U.S.
Key Facts
- Outlook Therapeutics (OTLK) is conducting a best-efforts public offering of common stock or pre-funded warrants and accompanying warrants.
- H.C. Wainwright & Co. is the exclusive placement agent.
- Proceeds will be used for working capital and general corporate purposes.
- The offering is made under a shelf registration (Form S-3) effective April 5, 2024.
- No specific offering size, price, or terms are disclosed.
- Company has a market cap of $29M and is not yet commercial in the U.S.
Financial Impact
Dilutive to existing shareholders; magnitude unknown pending final terms
Risk Factors
- Significant shareholder dilution depending on final offering terms
- Downward pressure on stock price due to oversupply of shares
- Market conditions may force unfavorable pricing or withdrawal of the offering
- Company remains pre-revenue in the U.S. with uncertain FDA approval timeline for ONS-5010
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260887 |
Track record
37 reports on OTLK
13 of 22 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 18 of 22 went positive at some point.
Filters
- Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
- Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
- Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
- Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
- Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
- Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers